JENSEN, Poul Erik Hyldgaard, Warnke, Clemens, Ingenhoven, Kathleen, Piccoli, Luca, Gasis, Marcia, Hermanrud, Christina, Fernandez-Rodriguez, Blanca, Ryner, Malin, Kramer, Daniel, Link, Jenny, Ramanujam, Ryan, Auer, Michael, Buck, Dorothea, Grummel, Verena, Bertotti, Elisa, Fissolo, Nicolas, Oliver-Martos, Begoña, Nytrova, Petra, Khalil, Michael, Guger, Michael, Rathmaier, Sandra, Sievers, Claudia, Lindberg, Raija, Hässler, Signe, Bachelet, Delphine, Aktas, Orhan, Donnellan, Naoimh, Lawton, Andy, Hemmer, Bernhard, Havrdova, Eva Kubala, Kieseier, Bernd, Hartung, Hans-Peter, Comabella, Manuel, Montalban, Xavier, Derfuss, Tobias, Sellebjerg, Finn, Dönnes, Pierre, Pallardy, Marc, Spindeldreher, Sebastian, Broët, Philippe, Deisenhammer, Florian, Fogdell-Hahn, Anna and Sorensen, Per Soelberg (2019) Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. Journal of neuroimmunology, 326. pp. 19-27. ISSN 01655728

Abstract

Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.

Item Type:	Article
Keywords:	multiple sclerosis; interferon-beta; luciferase-based bioassay; bridging ELISA; anti-drug antibodies; neutralizing antibodies
Date Deposited:	29 Nov 2018 00:45
Last Modified:	29 Nov 2018 00:45
URI:	https://oak.novartis.com/id/eprint/38284